CellSeed

CellSeed EBIT Margin

The EBIT Margin (Operating Margin) of CellSeed (7776.T) as of Oct 27, 2026 is -1,250.18 %. In the previous year, EBIT Margin (Operating Margin) was -437.91 % — a change of 185.49% (lower).

EBIT Margin

-1,250.18 %

YoY

185.49%

Last updated:

EBIT Margin (Operating Margin) of CellSeed is 2025 -1,250.18 % . EBIT Margin (Operating Margin) of CellSeed was 2024 -437.91 % . It decreases by 185.49% lower compared to the previous year.

For CellSeed, the operating (EBIT) margin of -1,250.2% is down versus -560.5% a few years ago.

The CellSeed EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
13.65 JPY
Jan 1, 2019
-299.46 JPY
Jan 1, 2020
-385.78 JPY
Jan 1, 2021
-560.48 JPY
Jan 1, 2022
-589.96 JPY
Jan 1, 2023
-366.99 JPY
Jan 1, 2024
-437.91 JPY
Jan 1, 2025
-1,250.18 JPY
The CellSeed EBIT Margin history
YEAREBIT MarginYoY
-1,250.18 %+185.49%
-437.91 %+19.32%
-366.99 %-37.79%
-589.96 %+5.26%
-560.48 %+45.29%
-385.78 %+28.83%
-299.46 %-2,293.80%
13.65 %-101.21%
-1,128.07 %+15.35%
-977.93 %+232.29%
-294.30 %-57.96%
-700.00 %+5,424.20%
-12.67 %-35.83%
-19.75 %-30.49%
-28.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

EBIT Margin (Operating Margin) of CellSeed is -1,250.18 % in 2025.

EBIT Margin (Operating Margin) of CellSeed changed from -437.91 % to -1,250.18 %, representing a 185.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) CellSeed since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s CellSeed with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — CellSeed

All Key Metrics — CellSeed